0001609351-16-000071.txt : 20160707
0001609351-16-000071.hdr.sgml : 20160707
20160707091835
ACCESSION NUMBER: 0001609351-16-000071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160705
FILED AS OF DATE: 20160707
DATE AS OF CHANGE: 20160707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spark Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609351
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462654405
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 888-772-7560
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: La Barge Joseph
CENTRAL INDEX KEY: 0001673526
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36819
FILM NUMBER: 161755607
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
4
1
wf-form4_146789750204183.xml
FORM 4
X0306
4
2016-07-05
0
0001609351
Spark Therapeutics, Inc.
ONCE
0001673526
La Barge Joseph
3737 MARKET STREET
SUITE 1300
PHILADELPHIA
PA
19104
0
1
0
0
See remarks
Common Stock
2016-07-05
4
M
0
3000
3.45
A
8325
D
Common Stock
2016-07-05
4
S
0
1900
51.92
D
6425
D
Common Stock
2016-07-05
4
S
0
1100
52.80
D
5325
D
Common Stock
200
I
Held by Reporting Person's immediate family members
Employee Stock Option (right to buy)
3.45
2016-07-05
4
M
0
3000
0
D
2024-07-01
Common Stock
3000.0
26429
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.45 to $52.36, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.47 to $53.09, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
25% vested May 24, 2015 and the remainder vests in equal quarterly installments over the following three years.
General Counsel and Head of Business Administration
/s/ Joseph W. La Barge
2016-07-07